Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by ZWJ Investment Counsel Inc.

Posted by on Apr 3rd, 2023

ZWJ Investment Counsel Inc. raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 7.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,586 shares of the biopharmaceutical company’s stock after buying an additional 3,075 shares during the period. ZWJ Investment Counsel Inc.’s holdings in Pfizer were worth $2,182,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Front Street Capital Management Inc. boosted its stake in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares during the last quarter. Lindenwold Advisors boosted its position in shares of Pfizer by 1.0% during the third quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 216 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Pfizer by 1.6% during the second quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock worth $714,000 after purchasing an additional 218 shares in the last quarter. Signet Financial Management LLC boosted its position in shares of Pfizer by 0.6% during the third quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock worth $1,503,000 after purchasing an additional 220 shares in the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. boosted its position in shares of Pfizer by 0.7% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock worth $1,487,000 after purchasing an additional 222 shares in the last quarter. Institutional investors own 67.62% of the company’s stock.

Insider Activity

In other news, major shareholder Pfizer Inc acquired 1,811,594 shares of the firm’s stock in a transaction dated Friday, March 17th. The stock was bought at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the transaction, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PFE shares. JPMorgan Chase & Co. set a $45.00 price target on shares of Pfizer in a research report on Monday, February 27th. Wells Fargo & Company reduced their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a report on Wednesday, January 4th. StockNews.com assumed coverage on shares of Pfizer in a report on Thursday, March 16th. They set a “buy” rating on the stock. Finally, Berenberg Bank set a $40.00 price objective on shares of Pfizer in a report on Tuesday, February 7th. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $50.38.

Pfizer Stock Up 1.0 %

Shares of PFE stock opened at $40.80 on Monday. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The firm’s fifty day moving average price is $41.98 and its two-hundred day moving average price is $45.61. The firm has a market capitalization of $230.29 billion, a P/E ratio of 7.45, a PEG ratio of 1.37 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. During the same period in the previous year, the business earned $1.08 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 3.3 EPS for the current fiscal year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.